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Abstract 
 
Cellular Trafficking of Single and Multiple Vectors 
 
Publication N° ___________ 
 
Silvia Ferrati, Ph.D. 
 
Supervisory  Professor: Mauro Ferrari.Ph.D. 
 
Nanomedicine is an innovative field of science which has recently generated 
many drug delivery platforms with exciting results. The great potential of these 
strategies rely on the unique characteristics of the devices at the nano-scale in terms of 
long time circulation in the blood stream, selective accumulation at the lesions sites, 
increased solubility in aqueous solutions, etc. 
 Herein we report on a new drug delivery system known as a multistage system 
which is comprised of non-spherical, mesoporous silicon particles loaded with second 
stage nanoparticles. The rationally designed particle shape, the possibility to modulate 
the surface properties and the degree of porosity allow these carriers to be optimized for 
vascular targeting and to overcome the numerous biological barriers found in drug 
delivery. 
 In this study we investigated the intra and inter cellular trafficking of the 
multistage system in endothelial cells bringing evidence of its bio-compatibility as well 
viii 
 
as its ability to perform multiple intra and inter cellular tasks. Once internalized in cells, 
the multi-particle construct is able to dissociate, localizing in different subcellular 
compartments which can be targeted for exocytosis. In particular the second stage 
nanoparticles were found to be secreted in microvesicles which can act as mediators of 
transfer of particles across the endothelium and between different endothelial and 
cancer cells. 
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1 Background 
1.1 Nanomedicine 
When we talk about nanotechnology we refer to engineered particles or devices 
that have at least one dimension between 1 to 100 nanometers (nm), but in a broader 
classification we can extend the dimensions to 1000 nm 1. The underlying rationale for 
this area of study is that at the nano-level particles or devices gain functional and 
chemical-physical properties that are not found in the equivalent bulk materials. 
Nanotechnology has wide applications ranging from biosensors, microchips, molecular 
switches, etc. The application of this new field of science to medicine for treatment, 
diagnosis and monitoring of disease has been recently referred by the National Institute 
of Health in the USA as ‘nanomedicine’.  
Since cancer is a leading cause of mortality all around the world, there is an 
acute interest in developing new nanosystems to help find a cure for this malignancy 2. 
A vast area of research is dedicated to developing new nano-delivery systems for pre-
approved drugs, especially chemotherapeutic agents 2a, 3. Nanotechnology applied to 
medicine has strong potential in helping to achieve the goal of delivering drugs to the 
site of lesion, at the right time in a controlled fashion and at an effective therapeutic 
concentration 2c, 4. Ideally, these systems will permit a more specific accumulation of 
the drug at the lesion, therefore increasing its efficacy and reducing side effects. In 
particular, nanoparticles attract large amount of interest given their characteristic size 
and the possibility to conjugate them with targeting ligands 5 (peptides, antibodies, 
aptamers etc.) which selectively recognize cancer cells or tumor microenvironment such 
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as vasculature 6 or stroma 7. For instance folate, 8 peptides such as RGD 9 and antibodies 
like anti-HER have been employed to target nanoparticles to the tumor site.  
Most of the current chemotherapeutic agents are small molecules with a broad 
pharmaco-kinetics which also causes them to interact with healthy tissues causing side 
effects such as alopecia, nausea and bone marrow damage.  In addition, these drugs are 
easily excreted by the body and, therefore, high-concentration injections are required to 
assure the therapeutic efficacy dosage, further increasing the toxicity. Most 
chemotherapeutics are also hydrophobic molecules and are currently administered 
solubilized in solvents that are toxic, such as cremophor EL.  
In conventional nano-micro drug carriers, the therapeutic agent is encapsulated 
or attached to particles which facilitates the solubility of the drug in aqueous solvents 
and protects the drugs from enzymatic degradation, improving its stability. Moreover, 
the encapsulation in particles combined with the targeting agents, facilitates cellular 
uptake enhancing drug accumulation at the target site.  
Many types of nanoparticles for drug delivery, imaging and diagnostics have 
been developed in the past two decades, in particular, liposomes, polymeric 
nanoparticles, micelles, Qdots, dendrimers, gold, super-paramagnetic iron oxide, silica 
and silicon particles. Doxil and Abraxane are two well-known FDA-approved 
chemotherapeutic nano-formulations already available on the market. Doxil is the 
liposomal formulation of doxorubicin used for many types of cancers such as leukemia, 
breast, lung and ovarian 10. Abraxane is instead a water soluble formulation of 
paclitaxel complexed with albumin nanoparticles which avoid the use of the toxic 
solvent Cremofor 11. Nanomedicine has also improved the delivery of genes 12 and 
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siRNA 13 14 offering an alternative to viral vectors. Nanoparticles conjugated to 
transcription activated proteins (TAT) are rapidly and efficiently delivered to the 
perinuclear localization in cells improving gene expression. In 2008 a phase I clinical 
trial was conducted to study intravenously injected polymeric targeted nanoparticles 
containing siRNA on patients affected by solid tumors15. The trials showed a significant 
down-regulation of the specific gene of interest. Inorganic nanopaticles such as Qdots 16 
and superparamagnetic iron oxide 17 (SPIOs) have instead been extensively studied as 
imaging contrast agents. Qdots present several appealing characteristics for imaging 
such as the ability to tune their fluorescent emission, a broad absorption range, a high 
quantum yield and almost negligible photobleaching. On the downside their application 
in vivo is limited by their toxicity 16 which makes optimized coatings necessary. Super-
paramagnetic iron oxide nanoparticles (SPIOs) on the contrary are made of 
biodegradable iron and their surface can be coated with various polymers that allow 
further conjugation of targeting molecules 18. SPIOs are currently available in various 
sizes and are used as contrast agents for magnetic resonance imaging (MRI) 19.  
 
1.2 Biological Barriers 
Both drugs and particles have to bypass multiple biological barriers before 
reaching the target site 20. Among these barriers there are: sequestration by the reticulo-
endothelial system (RES), transport across vascular endothelium or gastrointestinal 
epithelium, diffusion in the stroma and crossing of cell and subcellular organelle 
membranes 21. As a result, only a minimal percentage of the drug reaches the lesion site 
while the largest percentage accumulates in healthy organs, causing side effects. 
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These processes involve mass transport at multiple levels and in order to 
understand the mechanisms that govern transport across these biobarriers and develop 
more effective therapeutics it is necessary to bridge different scientific fields such as 
biology, chemistry, physics and mathematics. In this regard nanomedicine, which is per 
se a multi-disciplinary field, has brought an important contribution to the field of drug 
delivery, developing carriers that, given to their small dimensions and unique surface 
properties, have been able to reduce macrophage uptake and increase drug accumulation 
at the tumor site. However, a deeper understanding of the ‘oncophysics’ is necessary to 
develop more refined carriers and devices in order to successfully overcome these 
biological barriers and fight cancer.  
1.2.1 Endothelial Barrier 
In order to reach the tissue level the injected drug/carriers have to leave blood 
circulation and cross the endothelial barrier.  The endothelial cells lining the blood 
vessels constitute a size-selective semipermeable barrier that tightly controls the 
diffusion of molecules from the blood to the interstitial space 22. Two major mechanism 
of transport across the endothelial barrier have been identified: a paracellular pathway 
across the cell junctions and a trancellular pathway through the cells.  
The junctions between endothelial cells are mostly constituted by (VE)-cadherin 
bound to catenins, an interaction that is crucial for the regulation of permeability 23. The 
determination of molecules that can passively cross the blood vessel walls depends on 
the organ and type of endothelium. The brain, for instance, presents virtually no 
fenestrations while the remaining peripheral endothelium (capillaries) presents a cut off 
of 6nm which allow small molecules to pass through the junctions between cells 24. 
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Less continuous capillaries are also found in the kidney and liver with openings that can 
reach 40-50nm 25. In the presence of inflammation or disease, like cancer 26, mediators 
such as VEGF disrupt intracellular-junction organization, causing larger fenestrations 
up to 2 µm, which make tumor blood vessels more permeable than regular organs. In 
addition, tumors present a defective lymphatic system which contributes to the 
enhanced permeability and retention (EPR) effect responsible for the increased 
accumulation of macromolecules and fluids in the tumor region 27. Many drug delivery 
systems, such as liposomes, exploit this unique pathophysiology of the cancer 
vasculature to passively target particles of 100-150nm to the tumor site 27b, 28. 
The transcellular pathway is mostly exploited by macromolecules larger than 
3nm 25. This mechanism, also known as receptor mediated transcytosis or carrier 
mediated transport, involves the interaction of the cargo with transporters or receptors 
expressed on the endothelium surface 22a. Caveola, which is a membrane protein 
expressed in 70% of the capillaries, is the major vesicular transporter in endothelial 
cells. Caveola’s interaction with the cargo activates a mechanism of endocytosis with 
membrane invagination of 50-100nm in size (caveolae) which pinch off creating 
vesicles that traffic across the endothelial barrier, transporting the cargo. The study of 
these types of interactions can provide ways to exploit these receptors and selectively 
transport carriers and drugs across the endothelium 29. Thus a new generation of 
nanoparticles involves the functionalization of the carriers with moieties that improve 
these specific interactions which increase accumulation at the target site. A good 
example is Abraxane, in which the interaction of albumin with the gp60 endothelial cell 
membrane protein was exploited to facilitate the transport of the therapeutic agents to 
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the tumor site 11. Along the same lines, recently cRGD conjugation on doxorubicin 
polymeric micelle has been shown to improve uptake by tumor endothelial cells 
overexpressing ανβ3 integrins 30. 
1.2.2 Stromal Barrier 
Once extravasated from the blood stream, the carriers encounter the stroma 
which constitutes an additional barrier to the penetration of the particles inside the 
tissue 31. Multiple factors affect this transport-step, in particular the degree of 
vascularization of the organ, the extracellular matrix composition 32, the presence of 
inflammatory cells and the cell density 32-33. All these factors affect the tortuosity of the 
path that the carriers have to perform to reach the target cells 31. Moreover the stroma 
not only reduces the diffusion of the therapy in the tissue and therefore its efficacy, but 
because of the complex network of interactions between cancer cells and the tumor 
environment, promotes tumor growth providing a permissive environment in terms of 
nutrients, soluble factors, differentiation stimuli and fluid exchange.  
The critical importance of these interactions was first proposed by Paget in 
1889, when he suggested the ‘soil and seed’ theory 34. He hypothesized that the tumor 
cells are like seeds that prefer to grow in hospitable soil. Now this idea is well 
recognized and evidence of the stroma’s influence on angiogenesis, tumor growth, 
invasion and metastasis have been reported. Each tumor type presents, however, a 
characteristic stroma which can offer specific targets for therapies and potential markers 
for disease prognosis. For instance, a high level of tumor-associated macrophages has 
been correlated with poor prognosis for glioblastoma and breast cancers 35, or the 
extensive fibrosis in pancreatic cancer has been associated with the highly malignant 
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phenotype of the disease 36. Anti-angiogenic therapies developed to block VEGF 
pathway 37, such as Avastin, fall into the category of therapies that target the tumor 
environment and have shown good results. Another example is anti-TGF agents that 
target pancreatic stroma in order to reduce the fibrosis and improve chemotherapy 
efficacy 38.  
1.2.3 Cellular Barrier 
Many drugs elicit their efficacy once internalized in cells, acting on specific 
intracellular organelles. Therefore, once the carriers reach the target cells, they will 
encounter the cellular membrane as the next barrier. There are several mechanisms by 
which a particle can be taken up by a cell, such as endocytosis, phagocytosis and 
clathrin – dependent or clathrin – independent endocytosis.  
Different characteristics of the carriers such as size, charge, shape and material 
can dictate which pathway will be preferred and this will influence the final localization 
of the carrier inside the cell and its potential toxicity. Understanding how these factors 
influence the uptake and the intracellular trafficking of nanoparticles is helpful in order 
to rationally design carriers. Particles smaller than 500 nm can be internalized by cells 
through endocytosis 39. The presence of specific ligands on the particles can further 
target them through this pathway triggering receptor mediated endocytosis. In both 
cases the cell membrane invaginates, creating vesicles (called cavaeolae) presenting a 
size up to 500nm, which will encapsulate the particle or macromolecule, transporting 
them inside the cell 40. Particles bigger than 1µm are instead internalized by 
phagocytosis which requires the elongation of the cellular membrane (pseudopodia) in 
order to reach and engulf the particles 39. Clathrin-mediated endocytosis also involves 
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the interaction of the cargo with specific membrane adapter proteins which trigger the 
invagination and formation of clathrin-positive vesicles which mediate the particle 
transport inside the cells 40. For all the above pathways, once the vesicles are formed 
and internalized, they fuse with late endosomes and subsequently with lysosomes as 
part of their traffic toward perinuclear localization 41. Clathrin-independent traffic 
instead avoids this fusion.  
Not only the size, but also the particle geometry can influence the mechanism 
and rate of uptake. A systematic study conducted with macrophages correlated particles 
size and shape with three potential up-take outcomes: successful phagocitosis, 
attempted phagocytosis and unsuccessful phagocytosis 42. The initiation of 
internalization was driven by Ω, defined as the angle between the particle and the cell 
membrane (correlated to the shape), but the completion of the process was shown to be 
regulated by the volume of the particle. Moreover, since phagocytosis requires a 
massive energy-consuming actin rearrangement with the formation of pseudopodia that 
surround the particle following its geometry, particles whose geometry requires less 
expansion of actin are more easily internalized. Mathematical models, integrating 
particle-physico-chemical characteristics with biological parameters such as vascular 
transport and margination have also been developed in order to predict the degree and 
rate of particle uptake 43.  Using these models, maps predicting the propensity of a given 
carrier to adhere and be internalized by cells were developed. 
 Targeting moieties based on receptors or antigens overexpressed on diseased 
cells or associated vasculature can also be used to direct the internalization through 
receptor-mediated endocytosis 9b, 39. Among the several methods available to find 
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signature markers, there is the in vivo phage display44, which has been used to identify 
various tumor endothelial cell markers such as ανβ3 and ανβ5 integrins, CRKL, 
GRP78, etc.  Other targets such as the folate receptor 8, LHRH receptor 45 and PSMA 46 
47
 are instead expressed on tumor cells. Liposomes conjugated to folic acid have been 
shown to be internalized by tumor cells faster through endocytosis compared to naked 
liposomes, proving increased up-take specificity. Many folate-based carriers have been 
recently developed and are currently undergoing testing in clinical trial. LHRH peptide 
has been instead used to target campothcin to ovarian, breast and prostate tumors 48. 
Along the same line, a PSMA-targeting aptamer has been used to target PLGA-PEG 
nanoparticles- containing cis-platinum to prostate cancer cells 49.  
 
1.3 Secretion of Nanoparticles  
Even if nanoparticles have shown great promise as drug carriers there are still 
several fundamental problems that have to be understood and solved in order to refine 
their use. Intracellular trafficking of micro and nanoparticles has been extensively 
studied over the past decades. Particular interest has been spent in characterizing the 
endocytosis and intracellular localization of the particles, but less focus has been given 
towards investigating the long term retention of the particles in cells and their potential 
secretion into the surrounding area.  
Nanoparticles commonly enter into cells through endocytosis or phagocytosis, 
resulting in their encapsulation in vesicles (early endosomes). These vesicles can then 
mature into late endosomes, also called multivesicular bodies, and subsequently fuse 
with either lysosomes or autophagosomes, in a complex pathway which creates various 
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types of intracellular vesicles: amphisomes, autolysosomes and lysosomes 50. 
Hypothetically, at any point, the pathway vesicles can be recycled to the cellular 
membrane and released outside. Depending on the size and morphology, the secreted 
vesicles are classified as: exosomes 51, less than 100nm in size, released by a wide range 
of mammalian cells such as the cells of the immune system; microvesicles 52, 100nm-
1µm, released by stimulated cells; and apoptotic bodies, larger than 1µm, released at the 
end of cellular apoptosis. A few studies have reported the exocytosis of nanoparticles 
such as PLGA53 and iron oxide particles54 and single walled nanotubes55, opening a 
new, interesting field of research. The process is dynamic and it is hard to precisely 
quantify the rate of endocytosis and exocytosis at the same time. Through microscopy 
and single particle tracking Jin et al. has shown that the rate of exocytosis closely 
matches the rate of the internalization of particles55. In the context of endothelial cells, 
the exocytosis of PLGA particles in human vascular smooth muscle cells has been 
reported 53, showing that the process depends on the presence of serum in the medium. 
This suggests the involvement of opsonization in directing the internalized 
nanoparticles through the exocytic pathway. However, the mechanism by which these 
particles are released and the extent of this phenomenon across different cell lines is still 
not clear.  
Gauze 54c et al. have shown that iron oxide nanoparticles can be released in 
micro-biovesicles by macrophages, which are known to be able to shed their membrane 
in physiological and pathological conditions such as stress, apoptosis or upon 
activation, creating bio-vesicles which are released into the surrounding area. Similar 
evidence was found by Wilhelm et al. 56 which identified biovesicles containing SPIOs 
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released by eukaryotic cells. The nature of these nanoparticle-loaded vesicles, however, 
has not been investigated.  
Many questions are therefore still unsolved and the impact of exocytosis and 
inter-cellular transfer of nanoparticles on their biodistribution, therapeutic efficacy and 
imaging characteristics. 
 
1.4 The Multistage System 
1.4.1 Strategy 
Drug delivery carriers can be classified into 3 major classes: first generation 
carriers are naked particles, developed about a decade ago, that passively target tumor 
through EPR effect. Second generation particles added a level of complexity 
introducing surface decoration such as targeting moieties, environment-triggered 
activation, etc.; the third generation of carriers, instead, is composed of multiple nano-
elements able to perform specific tasks in order to sequentially negotiate the biological 
barriers that they will encounter during their journey from the site of injection to the 
target lesion. Our multistage system (MSV) is an example of this class of carriers.  
Our strategy is comprised of i.v. injectable stage 1 hemispherical nano-porous 
silicon micro particles (S1MPs) loaded with stage 2 nano-particles (S2NPs) 57. S1MPs 
have been rationally designed through a mathematical model in order to optimize the 
three major processes that occur during the travel of the carrier in the blood stream: 
margination on blood vessels walls, adhesion on the endothelial cells and control of the 
internalization in cells 57-58. Non spherical particles were shown to be the best 
candidates as carriers since they drift better toward the vessel walls increasing the 
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probability of interacting with it. The mathematical model was confirmed with in vitro 
experiments employing a parallel flow chamber and in vivo experiments in which 
particles presenting different shapes were injected into animals bearing breast cancer; 
these in vivo experiments showed hemispherical particles accumulated in the tumor in 
greater numbers 59.  
Once docked to the vasculature of the lesion site, the S1MPs release their cargo 
which extravasates from the vasculature to reach the target. The schematic in Figure 1 
summarizes the principle of our system. Porous silicon (pSi), was chosen as the 
material, since it is FDA approved and it is compatible with biological systems given 
the byproduct of its degradation is silic acid, a biologically harmless chemical. 
Moreover the size, shape and porosity of the material can be tightly controlled through 
semiconductor fabrication techniques therefore giving precise control over the final 
design 60. In addition, the versatility of silicon chemistry allows the conjugation of the 
particles’ surface with active targeting moieties, polymers such as poly(ethylene glycol) 
(PEG), etc. to increase circulation time and tumor accumulation 61. 
The S2NPs loaded into the pores of the silicon carriers can be any type of 
nanoparticles from liposomes to micelle or polymeric particles which can also be loaded 
with therapeutic drugs, contrast agents or combinations of the two generating a vast 
selection of options. Metal nanoparticles such as SPIOs or gold can also be loaded and 
can function as contrast agents as well as thermo-ablation agents once the heat 
production is triggered by radio frequency or near infrared energy. This makes the 
system very versatile in terms of applications and possible payloads. Figure 2 
recapitulates the possible types and combinations of S1MPs and S2NPs as well as 
 surface functionalizations 
characteristic. 
Figure 1 Schematic summarizing the principle of our multi
porous silicon carriers are loaded with 
docking on the lesion vasculature
vasculature and reach the tumor cells
Courtesy of Nature Publishing Group
and particle parameters to highlight this 
-stage system. The S1MP 
nanoparticles (S2NP) and then i.v. injected
 the carriers release the S2NPs which
 (Tasciotti et. al. Nature Nanotechnology, 2008, 
). 
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1.4.2 S1MP Fabrication 
The fabrication of the S1MPs is comprised of a combination of photolithographic, 
reactive ion-etch, electro-chemical etch and particle release steps on heavily doped 100 
mm silicon wafers (p++, (100), <0.005 Ωcm). The 3.2 µm hemispherical particles are 
made by first depositing a sacrificial layer of silicon-rich silicon nitride on the wafer. 
This is followed by a photolithography process using AZ5209 photoresist to imprint a 
pattern of 2 µm diameter circles using a chrome-plated mask.  Then a series of reactive 
ion etches are applied to remove parts of the sacrificial silicon-nitride layer, exposing 
the surface of the wafer with 2µm holes.  The photolithographic resist is then removed 
using a ‘pirahna’ solution after which the wafer undergoes an electro-chemical etch 
(EC-etch) to create the porous layers of the particles.  The pore size, degree of porosity 
and thickness of the particles can be tuned during the EC-etch step by varying the 
electric current, chemical-solution concentrations and etching time. Based on the 
knowledge in fabrication protocols developed in our laboratories, and by modifying 
various parts of the standard process, we can produce particles with dimension ranging 
from 500 nm to 3.2 µm, with pores from 5 to 80+ nm, in both hemipherical and 
discoidal shapes. The high degree of porosity allows the loading of a large amount of 
S2NPs and, at the same time, control of their release profile based on particle 
degradation.  
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Figure 2 Versatility of our MSV in terms of size, shape, degree of porosity, surface 
properties (negatively and positively charge groups, PEG or other polymers, 
functionalization with antibodies, peptides, aptamers and fluorescent probes) and 
possible payloads (liposomes, micelles, inorganic/metallic nanoparticles, carbon 
nanotubes) (Biana et al. Accounts of chemical research, 2011, Courtesy of ACS 
Publication). 
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2 Methods 
2.1 Cell Culture 
Human microvascular endothelial cells (HMVECs) were received as a gift from Dr. 
Rong Shao (University of Massachusetts) and grown in EBM® medium,  (CC-4133®, 
Lonza, Walkersville) while Human Umbilical Vein Endothelial Cells (HUVECS), 
bought from  Lonza, Walkersville, Inc,  were cultured in  EBM®-2 medium (CC-3124® 
, Lonza, Walkersville). 
Both cell lines were grown in monolayers 80% confluent in at 37C in 5% CO2. Cells 
detachment was performed with 0.25% mg/ml trypsin solution (Clonetics). 
2.2 Porous Silicon Particles and Surface Functionalization 
Hemispherical silicon microparticles were manufactured by our group at the 
Microelectronics Research Center at University of Texas at Austin using lithographic 
techniques. Particles were produced in two sizes: 1.6±0.2 and 3.2±0.2 µm; with pores 
size ranging of 26±0.2 µm, for hemispherical one, and 53±0.2 µm for discoidal one.  
Particles were heated at 110ºC in piranha solution (1 volume H2O2 and 2 volumes of 
H2SO4) for 2 hours to oxidize their surface and create a negative surface charge. 
Washing steps with deionized (DI) water were used at the end of the oxidation process 
before re-suspending the particles in isopropyl alcohol (IPA), where they are usually 
stored till their use. 3-aminopropyl-triethoxysilane (APTES) was employed to create a 
positive coating on the particles. The conjugation was conducted suspending the 
particles in a solution of 0.5% (v/v) APTES in IPA for 2 hours at room temperature. 
Both modifications were evaluated checking the particles surface charge by zeta 
potential. In order to functionalize the particles with poly(ethylene glycol) (PEG), 
APTES-modified  particles were incubated for 1.5 hours with 10nM PEG-5000 (Laysan 
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Bio Inc.) in acetonitrile and subsequently washed with DI water to remove the un-
conjugated PEG. 
2.3 Scanning Electron Microscopy  
4x104 cells were seeded on silicon chip supports (Ted Pella, inc, Redding, CA) in a 24 
well plate. Upon confluence, cell were incubated for 15 min with 1.6 or 3.2 µm 
oxidized particles (ratio 10:1 particles per cell) at 37 ºC in serum-free medium. Cells 
were then washed with PBS, fixed with 2.5% glutardehyde (Sigma-Aldrich, Saint 
Louis, MO) and washed again in PBS.  Samples were then dehydrated incubating in 
progressively more concentrated solutions of ethanol (30%, 50%, 70%, 90%, 95% and 
100%) for 10 minutes each. As last step, cells were incubated 10 minutes with a 
solution of 50% (v/v) ethanol-hexamethyldisilazane (Sigma, Saint Luis, MO) followed 
by 5 minutes in 100% hexamethyldisilazane. Samples were dried overnight in a 
dessicator. Silicon chips were mounted on SEM stubs (Ted Pella, Inc. Redding, CA) 
with the help of conductive adhesive tape (12mm OD Pelco, Ted Pella, Inc. Redding, 
CA), sputtered with a 10 nm film of gold by means of a Plasma Science CrC-150 
Sputtering system (Torr International, Inc.) and then they were imaged with a FEI 
Quanta 400 FEG-SEM (high vacuum conditions, 20kV, spot size 5). 
2.4 Transmission Electron Microscopy  
HMVECs were grown at a concentration of 1x106 cells/well in a 6 well plate and then 
incubated 6 hours at 37 ºC with 1.6 and 3.2 µm hemispherical particles, either oxidized 
or APTES modified. After the samples were washed with PBS, the fixation step was 
performed with a solution of 2% paraphormaldehyde (Electron Microscopy Science, 
Hatfield, PA) and 3% glutaraldehyde (Electron Microscopy Science, Hatfield, PA) in 
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0.001 M phosphate buffer saline (PBS), pH7.4. Samples were then washed, treated with 
0.1% Millipore-filtered cacodylate buffered tannic acid and then stained with 1% 
buffered osmium tetroxide for 30 min followed by 1% millipore-filtered uranyl acetate.  
The samples were subsequently dehydrated in progressively more concentrated 
solutions of ethanol (30%, 50%, 70%, 90%, 95% and 100%) and then infiltrated with 
Epon resin. The resin-embedded samples were let polymerized in an oven at 60 ºC for 2 
days. A Leica Ultracut microtome (Leica, Deerfield, IL) was employed to obtain 
Ultrathin sections of the samples which were then stained with uranyl acetate and lead 
citrate in a Leica EM Stainer. Images were acquired with a JEM 1010 transmission 
electron microscope (JEOL, USA, Inc., Peabody, MA) with a voltage of 80 kV.   
The same procedure was used to investigate the trafficking of the MSV and SPIOs in 
endothelial cells. For the first experiment, HMVECs were grown in a 6-wells plate till 
80% confluence, were then incubated with the assembled MSV system for 24 hours (5:1 
particles/cell) and then processed for TEM. For the second experiment, HMVECs were 
plated at a concentration of 1x106 cells/well in a 6 well plate and then incubated 6 hours 
with PEI-SPIOs (7µg/ml). Cells were subsequently fixed and processed for TEM 
imaging. The same protocol was also carried out with HMVECs, 4T1 and MCF7 cells, 
after incubation overnight with microvesicles concentrated from the HMVEC’s 
supernatants well as with the concentrated microvesicles pellet. 
2.5 Confocal Microscopy  
HUVECs were let adhere overnight on 1.5 mm glass coverslips and then they were 
treated with 3.2 µm silicon particles (5:1 particles to cell ratio) for 2 hours at 37 ºC. 
After being washed with PBS, cells were fixed with 4% paraphormaldehyde, 
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permeabilized with a solution of 0.1% Triton X-100 and blocked with a solution of 1% 
Bovine Serum Albumin (BSA) in PBS. Cells were then stained with 200 nM Alexa 
Fluor 555-Phalloidin (Invitrogen, Carlsbad, CA). Coverslips were then mounted on a 
confocal glass slide using Vectashield mounting media (Vector Laboratories, 
Burlingame, CA). Images were acquired with a Leica DM6000 confocal microscope 
with a 63x oil objective. Particles were visualized using auto-fluorescence exciting with 
a 633 laser. 
In order to characterize the mechanism exploited by our particles to traffic inside cells, 
HMVECs were grown till 80% confluence on 1.5 mm glass cover slips and then they 
were incubated with 3.2 µm silicon particles for 5 hours. The behavior of cell in regular 
medium was compared to cells grown in medium containing 150 nM nocosazole 
(Sigma, St. Luis, MO). Cells were processed for confocal following the standard 
procedure of fixation, permeabilization and blocking as previously reported. FITC-
labeled anti-α-Tubulin monoclonal antibody (Abcam) at 1:200 dilutions was employed 
to stain the cell microtubules. Nuclei were stained with DRAQ5 (Biostatus Ltd) at 
1:1000 dilution. Coverslips were then as usual mounted on a confocal glass slide using 
Prolong Gold as mounting media (Vector Laboratories, Burlingame, CA). Images were 
acquired with a Leica DM6000 confocal microscope with a 63x oil objective. Particles 
were visualized using bright field. 
To confirm the particles co-localization with phagolysosomes we transfected a GFP-
NPC1 construct (kind gift of Dr. J. Suh at Rice University) into cells with the help of an 
Amaxa Electroporator. 1x10 6 cells were trypinized, resuspended in 100 µl of Amaxa 
HUVECs nucleofactor solution (Lonza, Walkersville, MD), combined with 5 µg of 
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DNA and transfected with the appropriate electroporator programmed ramp. Cells were 
then diluted in medium and immediately plated on a glass bottom dish. Upon reached 
confluency, cells were incubated for 2 hours with 3 different variation of paricles: 3.2 
µm 594-dylight (Pierce)-conjugated particles 3.2 µm and 1.6 µm APTES-modified 
particles, then washed with PBS , fixed and imaged with an 1x81 Olimpus Microscope 
equipped with a 40x objective. 
In order to investigate SPIOs trafficking in endothelial cells, 5x104 HMVECs were 
plated on an 8 well glass bottom confocal chamber slide (BD Falcon) and left to adhere 
overnight. After cell membrane staining for 10 minutes at 37C with 594 wheat germ 
agglutining (WGA) (Invitrogen), cells were incubated with 488-dylight (Pierce) 
conjugated PEI-SPIOs (5µg/ml final concentration) overnight. The samples were then 
fixed with a 4% paraphormaldehyde solution, mounted with prolong gold mounting 
medium on confocal slides and imaged with a A1 Nikon confocal microscope. 
For the staining of concentrated microvesicles, the pellet was instead fixed with 4% 
paraphormaldehyde solution, washed once with a solution of 0.1% BSA in PBS and 
then stained with Alexa Fluor 488-Lamp1 antibody, 1:50 dilution, (Santa Cruz 
Biotchnology ) for 1 hour at room temperature. The pellet was then washed with PBS 
and incubated overnight with 4T1 breast cancer cells, previously seeded in glass bottom 
confocal chambers. 4T1 were then fixed with 4% paraphormaldehyde, mounted with 
prolong gold and imaged with a confocal Nikon microscope. Reflectance was used to 
visualize the iron oxide nanoparticles contained in the FITC-labelled vesicles. 
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2.6 Live Microscopy 
For the live cell imaging, HMVECs (25x103 per well) were grown on a 24 well-glass 
bottom dish (Mat Tek corporation, Ashland MA). 3.2 µm or 1.6  µm APTES-modified 
particles as well as 3 variations of spherical silica beads (1, 2.5 and 3 µm) were added to 
the cells. The samples were visualized with a 1X81 Olimpus Micriscope equipped with 
a humidified 37 ºC incubator with 5% CO2 , images of 5 focal planes were taken with a 
20X at 5 minutes intervals for 19 hours. The more rapresentative shots are reported as 
still images, while the the remaning pictures were projected and compiled into movies. 
Particles tracking was permormed using Slide Book software, analyzing the x and y 
coordinates of the particles over time. The mean square displacements (MSD) were 
calculated with the following equation: 
∆ 	 
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From which, through fittings, it was possible to calculate the rate of intracellular 
trafficking. Calculations and fitting were performed with Excel. 
2.7 Fluorescence Microscopy 
For the quantitative analysis of the mitotic trafficking of microparticles, HMVECs were 
grown in a petri dish and subsequently incubated with 488-dylight (Pierce)-conjugated 
3.2 µm particles (10:1 particles/cell) overnight to ensure internalization. The population 
of cells presenting the highest fluorescence and therefore the higher number of 
particles/cell was selected with a Becton Dickinson FACS Diva Flow Cytometer and 
Cell Sorter (BD Bioscience, San Jose, CA). The sorted cells were then plated in glass 
bottom dish at 5 different concentrations, starting from 25000 cells and diluting 1:2 till 
800 cells per well. Every 24 hour for 6 days, bright field and fluorescent images of the 
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cells were acquired with a fluorescent microscope (Nikon TS 200) with a 20x objective. 
The number of particles per cell was manually determined from the images. 
2.8 Flow Cytometry 
1.6 µm APTES-modified particles were conjugated to a pH sensitive dye (pH Rhodo-
NHS Ester, Invitrogen, Carlsbad, CA), which becomes fluorescent in acidic pH. The 
conjugation between the carboxyl group of the dye and the amino group of the APTES- 
particles was conducted in DMSO directly adding the dye solution to the particles 
incubating for 2 hours at room temperature.  Particles were then washed twice with 
DMSO and twice with IPA to remove the un-bounded dye. Cells, plated on a 6 well 
plate, were starved in serum-free medium for 40 minutes before adding the pH-Rhodo-
particles at a 10:1 particles/ cells ratio. Plates were centrifuged at 1500 rpm to let the 
particles settle down before incubation at 37 ºC for different amounts of time. Cells 
were then trypsinized, fixed and analyzed with a Becton Dickinson FACS caliber and 
Cell Quest software. 
2.9 Enzyme-linked immunosorbent assay (Elisa) 
HUVECs, seeded at 50000 cell/well in 24-well plate, were incubated with either 3.2 µm 
APTES-modified particles or PEG-500 (5:1 particle/cell). 20 µg/mL zymosan was used 
as positive control for cytokines up-regulation. 100 µl of the cell medium was collected 
at different time points (1, 4, 24 hours) and stored at -80 ºC till analysis. The removed 
medium was each time replaced with fresh medium. Interleukin-6 (IL-6) and 
interleukin-8 (IL-8) were measured in the medium using the Human IL-6 and IL-8 
ELISA Kits (Cell Science) following the manufacture protocol. 
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2.10 Tube Assay 
HMVECs were pre-labeled by incubating them for 15 minutes at 37º C with orange cell 
tracker (Invitrogen, Carlsbad, CA). 4 x 104 labeled HMVECs were then seeded on 80 µl 
of matrigel (Geltrex, Gibco, Grand Island, NY) in a glass bottom confocal chamber slide 
(BD Falcon, San Jose, CA) in the presence or absence of 488-Alexa Fluor (Pierce- 
labeled 3.2 µm S1MPs and let adhere overnight. The slides were then imaged with a A1 
Nikon confocal microscope equipped with a 20x objective. 
2.11 Zeta Potential and Fourier Transform Infrared Spectroscopy (FTIR) 
The surface charges of 15 nm amino-polyethylene glycol (PEG) polymer coated SPIOs 
nanoparticles (NH2-PEG SPIOs) (Ocean nanotech, Springdale, Arkansas) and oxidized 
silicon particles were tested with a Zeta Potential Analyzer (Zeta PALS). Three 
measurements were taken in both PBS (pH7) and borate buffer (pH5) and the final 
value reported was the average. 
The qualitative analysis of the NH2-PEG SPIOs surface coating was performed with 
FTIR and compared to carboxylated SPIOs. Dried samples were applied directly to the 
on the diamond surface of a SMART ATR attachment on a Nicolet 6600 FTIR spectro-
photometer.  Data were collected with a resolution of 4cm-1 and as an average of 16 
readings. The peaks analysis was performed with Omnic Peak Identification software. 
2.12 Porous Silicon Particles Loading 
In order to assemble the multistage system, 1x10 7 3.2 µm S1MPs were dried from IPA 
overnight and then incubated with 100 µg of 15nm SPIOs in borate buffer (stock 
solution 1mg/ml) for 30 min at room temperature. Samples were then washed twice 
with DI water to remove the un-loaded SPIOs.  Porous silicon particles were recollected 
each time by centrifugation at 2000 rpm (Beckman Coulter Allegra X-22 Centrifuge 
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equipped with a 296/06 rotor). To evaluate the loading efficiency, we measured the 
content of iron in the washing solutions as well as silicon carriers pellet by means of 
inductively coupled plasma optical emission spectroscopy (ICP-OES) with a Varian 
Vista AX (power set at 1kW, plasma flow set at 15L/min, auxiliary flow of 1.5L/min 
and a nebulizer flow of 0.75L/min, 5 replicates). 
2.13 Inductively Coupled Plasma Optical Emission Spectroscopy 
In order to quantify the concentration of iron in the supernatant over time, HMVECs 
were seeded in a 6-wells plate, once reached 80% confluence, they were incubated with 
3x106  loaded MSVs per well. Free SPIOs (5µg) were used as comparison. After 12 
hours cells were washed to remove particles not yet up taken and fresh medium was 
added to obtain the actual initial iron concentration. The amount of iron present in the 
medium at this time point was subtracted by the initial amount of iron added. 
Conditional medium was then collected over time at 1, 3, 5 and 7 days. Cells were split 
after 3 days and the media from the two wells were summed at the end before analyzing 
iron content. Collected samples were concentrated by centrifugation at 4200 rpm for 30 
minutes and the pellets were then dissolved incubating with 10µl of 10-12 M 
hydrochloric acid, for 2 hours at 60 ºC shacking at 1300rpm. The samples were then 
brought to the same volumes (5ml) with spectrosol solution (CFA-C, Spectrosol Inc.) at 
pH8.5. Iron standards were prepared at concentrations of 10, 25, 50, 100, 250 and 1000 
mg/L. Spectrosol solution was used as blank while a solution of iron at 125mg/L was 
used as the quality control standard. 
50µl of an yttrium solution (stock solution 100mg/ml) were added to each samples and 
standard as internal reference. Iron content was quantified with a Varian Vista AX ICP-
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OES (power set at 1kW, plasma flow set at 15L/min, auxiliary flow of 1.5L/min and a 
nebulizer flow of 0.75L/min, 5 replicates). 
2.14 MTT Cell Proliferation Assay 
HMVECs were seeded into 96-well plates (5000cell/well in 200 µl medium) and left to 
adhere overnight. Cells were then incubated with 15nm Polyetilenamine (PEI)-coated 
SPIOs (Ocean Nanotech) at a concentration of 2µg/ml for 24 hours. The medium was 
then replaced with fresh medium and cell proliferation was checked at 24, 48,36 and 72 
hours adding 200ul/well solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
dipheniltetrazolium bromide (MTT reagent, Sigma) at 0.5mg/ml. Cells were incubated 
with MTT reagent for 2 hours and then the solution was replaced with 200 µl dimethyl 
sulfoxide (DMSO). After 15 minutes incubation at room temperature absorbance was 
measured at 570nm with a Synergy H4 plate reader (BioTek). 
2.15 Concentration and Magnetic Purification of Biovesicles 
HMVECs cells were cultured in a T150 flask and once reached 80% confluence they 
were incubated with 2µg/ml PEI-SPIOs for 12 hours. The medium was then replaced 
with fresh medium to remove non uptaken particles. Conditional medium from the cells 
was then collected at day 3 and concentrated by centrifugation (21000xg 5 minutes). 
The brown pellet obtained was then re-suspended in PBS and further purified with 
magnetic separation overnight employing a magnet cuvette holder (Ocean Nanotech). 
The separated pellet, containing the SPIOs, was then processed for further 
experimenting as follow. 
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3 Results and Discussion 
3.1 Intracellular Traffic of Porous Silicon Micron-Particles 
 
3.1.1 S1MPs Uptake by Endothelial Cells and Micro-Tubules Mediated Transport 
 
Like many particles carrying systems, our multistage system is i.v. injectable 
and therefore it will have to interact with endothelial cells, in order to reach the lesion 
site. Moreover, since the vasculature of many lesions, among which cancer, presents 
unique characteristics in terms of structure 27b and markers 62, endothelial cells are often 
the primary target for the drug delivery systems 6, 63. Therefore the study of the 
interaction of our system with endothelial cells is of fundamental interest to understand 
the mechanism of uptake and release of particles in cells as well as their 
biocompatibility.   
We employed microscopy techniques and in vitro assays in order to characterize 
the mechanism of uptake, intracellular localization of the carriers and impact of 
particles presence on cellular morphology, viability and cell cycle.  As a model for this 
study we choose two endothelial cell lines: human microvascular cells (HMVEC) and 
human umbilical endothelial cells (HUVEC). Size, shape and surface properties of the 
particles can influence their interaction cells and therefore the impact of these 
parameters on the mechanism of particle uptake was of particular interest for us. 
Endothelial cells acted as non-professional macrophages internalizing S1MP particles 
through a combination of phagocytosis and macro-pinocytosi. Both mechanisms relied 
on an extensive actin rearrangement that led to an actin cup formation which 
surrounded and engulfed the particles. The early steps in the internalization of particles 
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were documented in a previous work with scanning electron microscopy (SEM) 
micrographs64. The process looks similar for both 1.6 or 3.2 µm SIMPSs with cellular 
pseudopodia elongating and reaching the particles within 15 minutes incubation with 
HUVECs at 37ºC. The subcellular localization of S1MPs was investigated by 
transmission electron microscopy (TEM) and confocal microscopy. 1.6 and 3.2 µm 
silicon particles, positively and negatively charged, were employed for this experiment. 
The surface modification of the particles was achieved by oxidation with piranha 
solution and 3-amino-propyltriethoxysilane (APTES) conjugation, respectively. 
HMVEC cells were incubated with particles for 6 hours and then fixed and prepared for 
TEM. The micrographs show the internalized particles localized in vesicles 
(phagosomes). The magnifications in Figure 3 clearly show the tight membrane 
surrounding the particles, for both particles sizes (Same result were obtained for 
oxidized particles, data not reported). Confocal images of HUVECs incubated for 60 
minutes with oxidized S1MPs and subsequently stained for actin were also acquired. 
 
 
 
 
  
 
 
Figure 3 TEM micrographs of APTES modified particles incubated with HMVECs for 6 
hours. In the top two images the particles are 3.2 µm in size while in the bottom two they 
are 1.6 µm in size. (Ferrati et al.’ Intracellular trafficking of silicon particles and logic-
embedded vectors’ Nanoscale 2010, Courtesy of RSCPublishing). 
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Subcellular details, such as organelles and nuclei, displayed in TEM images 
appeared healthy. In addition the surface charge and size did not seem to influence the 
compatibility of the particles to be internalized by endothelial cells or the characteristics 
of the vesicular compartments that housed them.  
Once formed inside the cell, the phagosomes fused with endosomes and later on with 
lysosomes in a process of maturation that requires the transient association of several 
different proteins on the vesicles membrane. EEA1 and Rab5 proteins play a role in the 
early stage of maturation while Lamp1 and NPC1 are recruited in the later stages. These 
motor proteins are necessary to traffic the phagosomes into the cells, docking them on 
the microtubules. This mechanism promotes a centripetal movement of the vesicles 
which brings them into the perinuclear area. In order to understand if our particles were 
moving inside the cells, exploiting the same trafficking mechanism, we incubated 3.2 
µm S1MP particles with HMVECs cells for 6 hours in the presence or absence of 150 
nM Nocodazole, which disrupts microtubules, thus inhibiting this specific trafficking 
mechanism. Cell nuclei were stained with DRAQ5 and the microtubules were stained 
with a FITC-labeled α-tubulin antibody. To evaluate the particles distribution in the 
cells with respect to the nuclei, cells were divided into quadrants presenting defined 
distances from the nuclei and the number of particles per quadrants was evaluated 
(Figure 4). The nocodazole-mediated disruption of microtubules reduced particles 
ability to accumulate in the perinuclear area by 80%. This provided insight into the 
intracellular mechanism of transport of the particles which resulted microtubules 
mediated and not randomly diffusive.  
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3.1.2 Maturation of Phagosomes Bearing S1MPs 
A well-known property of mature phagosomes is their acidity. The pH of the 
vesicles slowly decreases from 7 to 5 as phagosomes fuse with late endosomes and 
lysosomes. To evaluate the integrity of the pathway and the long term fate of the 
internalized particles we conjugate a pH sensitive dye (pH Rodo, Invitrogen) on the 
surface of 3.2 µm silicon particles, which emits fluorescent light in acidic environments. 
We then tested the pH-Rhodo particles measuring the increase in fluorescence of the 
particles in solution presenting different pH levels. This confirmed an increase in 
fluorescence, from 2.2 to 27, passing from pH 7 to pH 4. We then tested these particles 
in HMVECs performing a time-course incubation experiment evaluating cell 
Figure 4 Confocal images of particles internalized with 
regular HMVECs (top figure) or nocodazole-treated
HMVECs (bottom row). Cells were stained with a FITC-
α-Tubulin antibody for microtubules and DRAQ5 for 
nuclei (Ferrati et al. ‘Intracellular trafficking of silicon 
particles and logic-embedded vectors’ Nanoscale 2010, 
Courtesy of RSCPublishing). 
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fluorescence a different time points. This showed an increase in the mean fluorescent 
intensity of cells over time from an average of 5 at time zero, when the particles are still 
on the cell surface, up to an average of 19 after 16 hours of incubation (Figure 5 A). We 
observed a slightly decrease in intensity at 24 hours which may occur because of 
particles degradation or cleavage of the dye from their surface. 
Overall this data indicates that the vesicle traffic machinery is not negatively 
affected by our particles and phagosomes containing S1MP are still able to mature and 
accumulate in the perinuclear region moving along the microtubules. To confirm  
particle co-localization with phagolysosomes we trasnfected HMVECs with a construct 
presenting GFP fused with Nieman Pick C1 (NPC1) in order to specifically label the 
lysosomes. Next we incubated the trasfected cells with Dylight 594-labelled 3.2 µm 
particles and imaged with confocal microscopy. Figure 5B shows the acquired images 
in separate and combined channels to highlight the GFP-NPC1 expression (the green 
ring) in the membrane surrounding the internalized particles, which suggests the 
localization of particles in lysosomes. Since the presence of the fluorophore on the 
particles could theoretically influence the intrinsic traffic of the carrier, we also 
performed the experiment with 1.6 and 3.2 µm unlabelled particles, obtaining similar 
results (Figure 5C).  
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3.1.3 Intracellular Mobility and Trajectory of S1MPs 
In order to further evaluate the effect of size, shape and charge on the 
intracellualr traffic of the particles we evaluated and compared the trajectory, 
directionality and rate of migration toward the perinulcear region of different 
varaiations of carrriers employing real time confocal microscopy. In particular we 
analyzed 1.6 and 3.2 µm hemispherical porous silicon particles, positively and 
Figure 5 A) Flow cytometry analysis of pH-Rhodo-conjugated particles incubated for 
up to 24 hours with HMVECs. The cells mean fluorescence is reported over time. B) 
and C) Confocal images of  GFP-NPC1 transfected HMVECs incubated for 4 hours 
with either dylight 594-conjugated silicon particles B) or un-labeled particle C). The 
images are presented in merged and separated channels (Ferrati et al. ‘Intracellular 
trafficking of silicon particles and logic-embedded vectors’ Nanoscale 2010, Courtesy 
of RSCPublishing). 
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negatively charged, as well as three sizes of spherical beads (1, 2.5 and 3 µm). Movies 
compiled by assembling images taken every 5 minutes for 19 hours over 5 focal planes, 
were used to manually track particles inside the cells, from the moment they interacted 
with cell surface until they reached the perinuclear region (Figure 6 A). The two-
dimensional time- dipendent coordinates [, ] of the particles were used to 
calculate individual time-averaged mean square displacement  (MSDs) employing the 
following equation: 
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Where  is the 5 minutes time lag between image acquisition. 
Once generated, the MSD curves were fitted with the equation:  	 6   
(fitting 1 Figure 6 B). In the specific case of k=1 the equation becomes Fick’s law, 
which describes random, thermally driven diffusion. When   1 instead, the equation 
describes the active transport where molecules or particles migrate toward a defined 
direction. All of the MSD curves were fitted with the equation presenting   1 which 
confirmed that the particles were moving inside the cells with an active transport that 
we previously found to be microtubule mediated. Transport rate for active traffic can be 
calculated using the following equation: ∆  	 4   (Fitting 2 Figure 6 B) 
where the two terms describe respectively the random diffusion and the active 
contribution with  the diffusion coefficient and  is the rate of intracellular trafficking. 
We calculated the rate of perinuclear migration of multiple particle variations obtaining 
a consistent average rate of 0.5 µm per minute for all samples (Anova test with P=0.005 
was used to compare the populations). This result, reported in Figure 6 B in the box 
charts, suggested that the rate of intracellular migration of the particle-loaded 
 phagosomes is not influenced, at least in 
3.2 µm) the shape (hemispherical and spherical) and the charge (negative and positive).
Figure 6 Intracellular rate of migration: effect of size and shape. A) Example 
of manual tracking of a single 
with the cellular membrane till the point it reaches the perinuclear localization.
Images acquired each 5 min with confocal microscope (scale bar 10
Top graph represents an example of MDS curve fittings
as box charts the rates of perinuclear migration of different types of micro
particles: oxidized (ox) and APTES 
(1.6 and 3.2 µm) and spherical silica beads in three sizes (1, 2.5 and 3 
(Ferrati et al. ‘Intracellular trafficking of silicon particles and logic
embedded vectors’ Nanoscale 2010, 
the used range, by the particles size (1.6 and 
particles from the moment it start interacting 
µm). B) 
. Bottom graphs report 
– modified hemispherical silicon particles 
Courtesy of RSCPublishing). 
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3.1.4 Mitotic Trafficking 
For biomedical application it is important to understand the impact of particles on 
cellular events such as the cell cycle. The effect of the particles presence as well as their 
redistribution during proliferation could potentially introduce disparities and challenges 
in imaging or treatment of the cells. We therefore investigated the ability of cells 
containing particles to undergo mitosis by means of real time confocal microscopy, with 
particular interest on the fate of the particles. Taking images in five focal planes every 5 
minutes for 24 hours, we 
were able to capture the 
all sequence of events 
during the mitotic process 
of HMVECs-bearing 
particles. The mechanism 
of endosomes traffic 
during mitosis involves 
microtubules, with a  
centripetal movement of 
vesicles toward the 
central region in the first 
part of the process, and a 
polarized partitioning 
along the intercellular 
bridges toward the end of the process. Mitotic traffic of endosomes-containing particles 
appear to follow the same mechanism, with the particles accumulating in the central 
• Figure 7 Real-time confocal imaging of HMVECs 
containing 1.6 µm particles undergoing mitosis. The 
white arrows highlight the initial cell and then the 
two daughter cells containing equal amounts of 
microparticles (Ferrati* and Serda* et al. ‘Mitotic 
trafficking of silicon microparticles’ Nanoscale, 
2009, Courtesy of RSCPublishing). *shared first 
authorship. 
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region after approximately 30 minutes from the beginning of the process (Figure 7, top 
right) and then migrating in the two daughter cells a later time points. During this highly 
ordered process organelles, such as endosomes, are therefore equally divided between 
two daughter cells. The integrity of the process was found to be unaffected by the 
presence. Figures 7 and 8 show indeed a time-lapse sequence of images of a cell, 
containing respectively 1.6 or 3.2 µm particles before the mitotic event, and equally 
partitioning the particles between the two daughter cells during the cellular division.  
 
Figure 8 Real-time confocal imaging of HMVECs containing 3.2 µm particles 
undergoing mitosis. The white arrows highlight the initial cell and then the two 
daughter cells containing equal amounts of microparticles (Ferrati* and Serda* et al. 
‘Mitotic trafficking of silicon microparticles’ Nanoscale, 2009, Courtesy of 
RSCPublishing) *shared first authorship. 
 
This is consistent with the fact that each S1MP is encapsulated in phagosomes, 
as we have shown in TEM micrographs, therefore each particle represents an endosome 
and follows the same fate of the single vesicles during the process. This study 
confirmed that particles are not compromising cellular function, resulting in compatible 
and safe use for in vivo study. Partitioning of S1MPs showed persistence over longer 
time points as it was monitored for 6 days by means of fluorescent microscopy. 
HMVECs were incubated with 3.2 µm fluorescently labeled particles and then sorted 
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with FACS to assure a homogeneous population of particles-containing cells. Number 
of particles per cell was manually counted each day using the bright field images to 
define cell boundaries and fluorescent images to evaluate particle content. Two 
representative images of days 2 and 6 are reported in Figure 9 A , the particles counts 
over time are reported as a Box and Whisker Chart  (Figure 9 B) where the statistical 
boxes summarize the 25th, 75th,50th percentiles and the average number of particles in 
the cells is written on top of each box. Significant changes in particles content, based on 
ANOVA test with P=0.005, were marked with an asterisk and well were correlated with 
the 48 hours doubling time of HMVECs. Indeed each 48 hours the average number of 
particles per cell decreases by half, confirming particle partitioning during mitotic 
events over time, for both 1.6 and 3.2 µm particles.  
 
 
 
 
 
 
 
 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.5 Direct Cell-to-Cell transfer of Silicon Microparticles. 
After having analyzed the impact of microparticles on endothelial cell 
proliferation and mitosis, we investigated the retention of particles within the cells and 
their possible intercellular transport. Real time confocal microscopy was employed to 
monitor HMVEC cells incubated with 3.2 µm oxidized silicon particles overnight. 
Direct cell-to-cell transfer was observed as reported in the time-lapse sequence of 
Figure 9 Quantitative analysis of the number of particles per cell during proliferation. 
FITC-labeled particles were incubated with HMVECs and then a homogenous 
population of cells with equal number of internalized particles was sorted at FACS 
based on fluorescence. A) Representative fluorescent images of HMVECs- containing 
particles at day 2 and 6. B) The number of particles per cells at different time points is 
represented through statistical box charts. The 25th, 75th (box margins) and 50th (middle 
line) percentiles and the average number of particle per cell per day (number on top of 
the box) are reported. Statistically different amounts are marked with a star (Ferrati*
and Serda* et al. ‘Mitotic trafficking of silicon microparticles’ Nanoscale, 2009, 
Courtesy of RSCPublishing) *shared first authorship. 
38 
 
pseudo colored (Figure 10A) and unaltered confocal images (Figure 10B). In the 
sequence of images a cell (colored in blue, which we called the ‘donor cell’) containing 
one particle, transferr it to the neighbor cell (red cell, which we called the ‘recipient 
cell’). The particle’s perinuclear localization in the donor cells and its movement 
associated with the cell migration suggested that the particle is fully internalized by the 
donor cell. At the moment of transfer the donor and recipient cells align each other and 
their membranes appear to expand and open to accommodate the particles. The 
transferred particle appears then to migrate to the perinuclear region of the recipient cell 
suggesting fully internalization.  
 
Figure 10 Real-time confocal imaging of HMVECs containing 3.2 µm particles at 
37ºC. Transfer of the particle between cells is highlighted by pseudo-coloring the cells: 
blue the donor cell and red the recipient cell (Top). TEM images of HMVECs incubated 
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for four hours with 3.2 µm particles. Scale bars are respectively 10 µm, 2 µm and 
500nm (Bottom). 
TEM micrographs of HMVECs treated for 4 hours with silicon particles (Figure 
10 C) show images of adjacent cells containing particles which would support the direct 
transfer between cells. The particles are indeed near the cells membrane boundaries, 
where the two membranes appear fused each other suggesting fusion of the two cells. In 
The TEM images we also observed particles in the area surrounding the cells enclosed 
in membranes (Figure 10 D), which could potentially be particles secreted by the cells.  
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Figure 11 Confocal images (Top) of HMVECs incubated with 3.2 µm particles at 37ºC 
(5:1 particles/ cells). Cells were stained with Alexa Fluor 555 Phalloidin while the 
particles are fluorescently labeled. Pseudo-colored SEM images (middle) of HMVECs 
interacting with 3.2 µm porous silicon particles. TEM micrographs (bottom) of 
HMVECs incubated with 3.2 µm particles at 37ºC for 4 hours. Pseudopodia containing 
particles are visible in both SEM and TEM images. (scale bar 10µm and 2µm 
respectively) 
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In addition Figure 11 top (Data generated by Dr. Rita Serda) shows confocal 
images of Alexa fluor Phalloidin stained HMVECs where pseudopodia connecting the 
cells presenting actin filaments is visible. Similarly elongated cellular structures 
connecting neighbor cells that also contain silicon particles are visible in SEM (Data 
generated by Dr. Rita Serda) and TEM images (Figure 11, middle and bottom). These 
types of pseudopodia are very close in structure to the tunneling-nanotubes (TNTs) 
which are thin tubular membrane protrusions known to be involved in communication 
65
, transfer of organelles and long distance connectivity between cells 66. TNTs have 
been shown to be exploited by cells for the intercellular transport of nanoparticles. Mi et 
al.67 followed the fate of quantum dots micron-aggregates in human hepatocellular 
carcinoma cells and observed transfer between cells happening through the formation of 
TNTs, which connected the two cells involved in the process. The particles transported 
along the TNTs were encapsulated in lysosomes and the whole organelle was 
transferred between the cells.   
Although these results cannot fully explain the transfer mechanism, they can 
qualitatively describe the process, highlighting the complexity and dynamicity of the 
interaction of cells with particles. 
Moreover Figure 12 reports another time-lapse sequence of confocal images 
acquired in the same experiment, but in a separate field of view. The images show the 
transfer of two particles between 2 adjacent cells (pseudo colored in pink and blue) 
mediated by a small active cell (green cell), which acts as a shuttle. This ‘shuttle cell’ 
transfers the first particles (Figure 12A) and then goes back to the donor cells (Figure 
12B) and picks up another particle. From the sequential images it is possible to see how 
 the donor cells is extended in the region where the transfer occurs and how the green 
cell precisely attached to that location and grab the particle.  
Figure 12 Real-time confocal imaging of
undergoing intercellular transfer. The cell
cellular margins and the white harrow points to the particle involved into the process.
 
The rate of inter-cellular transfer was also quantified 
System and Ideas software, in collabora
University of Swansea, in UK.
(Alexa Fluor 555) or green (Alexa Fluor 488)
 
 HMVECs containing 3.2 µ
s have been pseudo colored to highlight the 
by means of Imagestreaming X 
tion with Dr.Summers and Dr. Rees at the 
 Two populations of cells, respectively containing red 
-labelled microparticles, were co
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m particles 
 
-cultured 
 for 24 hours and dual labeled cells were qua
single labeled populations were used as controls to set up the spectral compensation. 
When the cells were co-cultured in regular mediun containing serum the exchange 
24 hours was 1% while when the cells were cultured in serum
increased to 5%. This indicates
possibility to manipulate the extent of the process.
 
This novel phenomenon brings up questions regarding the possibility of 
achieving long distance communication
appears that multiple different mechanisms such as d
Figure 13 Estimation of silicon microparticle exchange between HMVEC
were treated with single-label microparticles
culture for an additional 24 hr.  Imagestream X flow cytometer and
used to image cells and estimate 
microparticle between HMVEC in the presence and absence of serum
assessed. 
ntified with the system (Figure 1
-free media the exchange 
 an involvement of serum in the process and the 
 
 between cells with transfer of p
irect cell transfer, TNTs and cell 
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shuttling could potentially be involved in the transfer of micro-particles between cells 
bringing additional level of complexity to intra and inter cellular trafficking of particles. 
In addition the increase in the rate of exchange during serum-starvation may suggest 
that environmental stress might stimulate the exchange. This could be potentially 
exploited in tumor environment to rapidly distribute the particles and their payloads 
between cancer cells. 
3.2 Multistage Vectors 
3.2.1 Assembly and Characterization 
S1MPs were the first components in the assembly of our MSV system serving as 
carriers for S2NP that can be loaded into the porous structure. The loading procedure 
was based on capillary suction of the solution containing the S2NP into the pores of the 
S1MP. The entrapment and retention of the second stage depends on pore size and the 
electrostatic interactions between the nanoparticles and the porous silicon surface. Both 
of these parameters can be tuned to achieve the optimal condition for a given S2NP. 
This allows our system to be very versatile in terms of payloads possibilities.  
In order to study the impact of the MSV systems and its intracellular traffic in 
endothelial cells, we assembled the system loading S1MPs with SPIOs. SPIOs can be 
used as magnetic resonance imaging (MRI) contrasts agents given their ability to 
decrease the relation time, T2, when accumulating in a region. They are also employed 
as hyperthermia agents, targeted drug delivery and cell separation. SPIOs are 
commercially available in many sizes ranging from a few to hundreds of nanometers in 
diameter with several different surface coatings such as synthetic polymers and 
polysaccharides 17.  For the study we employed 15 nm SPIOs coated with amino-
polyethylene glycol (PEG) polymer (NH2-PEG SPIOs), since from previous studies 68 
45 
 
they resulted the best choice in terms of loading capacity into our MSV. The 
physicochemical characteristics of the nanoparticles were verified employing Zeta 
Potential analysis and Fourier Transform Infrared (FTIR) - spectroscopy. The particles 
charge, measured through zeta potential, was checked for NH2-PEG SPIOs and 
oxidized silicon particles both in phosphate buffer (pH7) and borate buffer (pH5). The 
NH2-PEG SPIOs net charge were -4mV and +31.2 mV respectively in phosphate (PBS) 
and borate buffer while oxidized porous silicon particles were respectively -22.5mV and 
-28mV, showing complementary electrostatic conditions between the two components 
of our system especially in borate buffer, which was therefore chosen as loading 
solution for multistage particle assembly. The stability of the SPIOs’ coating was tested 
by incubating the particles for 6 days in PBS (pH 7) and regularly testing the zeta 
potential in order to confirm the constant value of surface charge of the particles 
throughout the experiment. 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
FTIR spectroscopy 
carboxylated SPIOs (Figure
presence of  the characteristic 
cm-1 (CN) and the CH stretching at 2922
presented on both types of particles such as the bands at 1700
cm-1 (CH2-OH). 
The NH2-PEG SPIOs were loaded through capillary action into
discoidal silicon particles and the amount l
plasma optical emission spectroscopy (ICP
silicon particles ( 21% loading efficiency).
Figure 14 TEM micrographs of 3.2
15nm iron oxide nanoparticles (TOP image). 
(COO-IO) and amino-PEG (NH2
image) (Ferrati et al. ‘Intracellular trafficking o
embedded vectors’ Nanoscale 2010, 
was performed on NH2-PEG SPIOs and compared to
 14, bottom). NH2-PEG SPIOs spectrum highlight
peaks for primary amines at 3341 cm-1 (NH) and 1298 
 -2853 cm-1 in addition to the PEG bands 
 cm-1 (COOH) and 1104
 3.2 µm mesopourous 
oaded was evaluated by induced coupled 
-OES) resulting in 6.4µg of iron per 3 x 10
 TEM images, in Figure 14 top, 
µm porous silicon particles loaded with 
FTIR spectra of carboxylated 
-PEG-IO) iron oxide nanoparticles (bottom 
f silicon particles and logic
Courtesy of RSCPublishing). 
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particles loaded with the amino-PEG SPIOs, with a detailed zoom on the pores of the 
particles. 
3.2.2 Intracellular Traffic of MSV 
The intracellular trafficking of the MSV was studied in HMVECs cells 
employing TEM microscopy. At early time points (24 and 32 hours) it was possible to 
image the assembled system internalized in phagosomes into the cells. The SPIOs were 
still predominantly associated with the carriers although in some phagosomes, regions 
rich in nanoparticles started to dissociate creating separated vesicles containing SPIOs. 
In Figure 15 the sequence of events is recapitulated with particular focus on a 
membrane protrusion budding from the original endosome which will then form a 
unique vesicle free to independently traffic in the cytoplasm. This suggests an active 
sorting of the SPIOs from the carriers over time.  
We were also interested in understanding the long term fate of the S2NPs. 
Phenomenon of exocytosis of nanoparticles such as PLGA nanoparticles, carbon 
nanotubes or SPIOs have been reported in literature. 
 
 
 
 
 
 
 
 
Figure 15 TEM micrographs of multistage system after up take by HMVECs. The 
system was assembled loading porous silicon microparticles with 15nm amino-PEG 
SPIOs. Sorting of SPIOs in unique vesicles presenting characteristics of 
multivesicular bodies is visible overtime (Ferrati et al. ‘Intracellular trafficking of 
silicon particles and logic-embedded vectors’ Nanoscale 2010, Courtesy of 
RSCPublishing). 
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To evaluate possible exocytosis of our nanoparticles from HMVECs, we 
quantitatively measured the concentration of iron over time in the supernatant of cells 
incubated with the MSV employing ICP-OES. The data in Figure 16 B is reported as 
percentage of iron released with respect to the SPIOs effectively delivered. The latter 
was calculated evaluating the initial amount of iron delivered to the cells and 
subtracting the amount of free particles still present in the medium at 12 hours, since 
these particles were not internalized and therefore removed during the washing step. We 
also normalized the results for the iron presents in untreated cells. The amount of SPIOs 
released per day was found to be on average 25%. This result was compared to the 
release of free amino-PEG SPIOs not loaded into the multistage system which was on 
average lower (around 12%). The difference in secretion could be due to difference in 
trafficking and sorting of endosomes as well as a difference in absolute values of iron 
per cells which may impact the cellular secretion itself. 
TEM images (Figure 16 A) of MSV incubated in HMVEC cells for 7 days 
supported the decrease of SPIOs from the primary carrier over time. Together this data 
suggests an active release of S2NPs from the pores of the silicon particles with potential 
subsequent exocytosis of SPIOs. 
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3.3 Secreted Biovesicles as Mediator for Intercellular Transfer of 
Nanoparticles. 
The employment of nanoparticles for biomedical applications has brought up 
questions about their biodistribution in the body and their fate at a cellular level 69. Our 
mitotic trafficking data explained particles redistribution during proliferation while the 
transfer of micro-particles between cells and the preliminary results reporting the 
increase of iron concentration in the medium over time after treatment of endothelial 
Figure 16 Long term fate of SPIOs loaded into the multistage system.  A) TEM 
image showing the majority of SPIOs been released after 7 days incubation in 
cells. B) Increase of iron concentration in the medium over time after incubation 
of multistage (GP-NH) or free SPIOs in HMVECs (Ferrati et al. ‘Intracellular 
trafficking of silicon particles and logic-embedded vectors’ Nanoscale 2010, 
Courtesy of RSCPublishing). 
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cells with our MSV loaded with second stage SPIOs suggested possible secretion of 
both S1MPs as well S2NPs from cells. For S1MPs we saw that multiple mechanisms 
were potentially involved into the transfer such as TNTs and direct transfer, we next 
decided to further investigate the form and mechanism by which S2NPs were instead 
secreted from HMVECs. For simplicity, we employed free SPIOs as nanoparticles and 
we characterized their intracellular traffic briefly recapitulating their uptake mechanism 
in HMVECs and then focusing on their secretion. 
3.3.1 Endocytosis of PEI-SPIOs in HMVECs 
TEM micrographs (Figure 17 B-D) of HMVECs cells incubated with PEI-SPIOs 
for 6 hours show the uptake of particles by cells and their localization within 
endosomes. The encapsulation of the particles in vesicles was also confirmed by 
confocal microscopy (Figure 17 A). 488-labeled SPIOs were incubated with 594- Wheat 
Germ Agglutinin (WGA) stained cells. WGA selectively binds to N-acetylglucosamine 
and N-acetylneuraminic acid thus staining the cellular membrane, which, during the 
uptake of the particles, forms the endosomes. The co-localizing of particles within the 
vesicles resulted in a yellow coloration of the endosomes as the sum of the two 
fluorescent dyes (average overlap coefficient resulted 0.980). Early endosomes are 
known to be able to mature into late endosomes (also known as multivesicular bodies), 
which can then fuse with either lysosomes or autophagosomes forming respectively a 
mature form of lysosomes or hybrid structures such as amphisomes and autolysosomes. 
Both mature lysosomes and hybrid structures can retain markers of the original 
organelles, such as: Rab7, LC3 and Lamp1, which are markers for late endosomes, 
autophagosomes and lysosomes respectively. Therefore any of the markers can be used 
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to label these organelles. The maturation and fusion between organelles is associated 
with a movement toward the perinuclear region. From TEM and confocal images, the 
presence of SPIOs within the endosomes does not seem to affect their maturation and 
their final co-localization in the perinuclear region. 
Moreover, the internalization of the particles did not negatively impact the cells 
as both their morphology and subcellular structure, such as nuclei and organelles; 
appear healthy in the TEM micrographs. In addition, the MTT assay (Figure 18 A) 
confirmed that the cellular proliferation over 4 days of incubation with PEI-SPIOs (2 
µg/ml) was not affected.  
 
Figure 17 A) Co-localization of 488 Dylight labeled-PEI-SPIOs with 594-WGA-
labeled vesicles after overnight incubation in HMVECs. B) TEM micrographs of 
HMVECs incubated with PEI-SPIOs. Vesicles containing SPIOs are visible inside as 
well as outside the cell. 
 
3.3.2 Secretion of Microvesicles Containing SPIOs 
In our previous set of experiments we hypothesized that the increase of iron 
concentration in the supernatant was due to the exocytosis of second stage 
nanoparticles, released from the silicon carrier. In the present study we further 
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investigated this phenomenon to understand in which form the SPIOs were secreted. 
The TEM micrograph reported in Figures 17-C, clearly shows that endocytosed-SPIOs 
can be secreted into the surrounding area by HMVECs encapsulated into biovesicles. 
Next we analyzed the content of the conditional medium of HMVECs recovered after 
three days of incubation with PEI-SPIOs. We concentrated the supernatant by 
centrifugation obtaining a dark pellet (Figure 18 B), which suggested the presence of 
secreted iron nanoparticles.  
 
 
 
 
 
 
 
 
 
The ultrastructural characterization of the samples by TEM revealed the 
presence of vesicles containing nanoparticles (Figure 19). The vesicles have an average 
size of 1µm and from a morphological point of view they present various characteristics 
of multivesicular bodies (MVB) (Figure 19 A), autophagosomes (Figure 19 C) and 
primary lysosomes (Figure 19 B) containing recycled membrane bundles, smaller 
endocytic vesicles, partially degraded ribosomes and rough ER. Next we tested the 
presence of Lamp1 as a membrane biomarker for the biovesicles. 
A B 
Figure 18 A) MTT proliferation assay of HMVECs incubated with 
PEI-SPIOs. B) Concentrated conditional medium form HMVECs 
incubated for 3 days with PEI-SPOIs. 
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The concentrated pellet was incubated with a FITC labeled Lamp1 antibody and 
analyzed with confocal microscopy, using reflectance to visualize the clusters of iron 
oxide nanoparticles. Biovesicles containing iron nanoparticles appeared to be Lamp1 
positive as shown in Figure 21-A, confirming their endosomal origin. In addition it was 
previously reported that exocytosis depends on the molecular weight of the cargo: lower 
molecular weight molecules are recycled from early endosomes while higher molecular 
weight molecules are secreted from larger and slower compartments, presumably 
lysosomes 70. Exocytosis of fluid phase markers was therefore faster than the secretion 
of nanoparticles due to the different size and nature of the cargo 53. The release of 
SPIOs appears to be slow and it becomes substantial after 48 hours suggesting release 
from the slower compartment. 
We have schematically outlined in Figure 20 a possible mechanism for the 
release of vesicle-enclosed nanoparticles from endothelial cells. The first part of the 
schematic summarizes the well-established cellular uptake of nanoparticles through 
A B C 
Figure 19 TEM micrographs of concentrated medium form HMVECs incubated with 
PEI-SPIOs. The ultra-structural analysis revealed presence of secreted microvesicles 
containing SPIOs.( Scale bar 100 nm) 
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endocytosis, while the second part describes the rerouting of mature endocytic vesicles-
containing nanoparticles and their release outside the cell. 
  
Figure 20 Schematic of proposed mechanism of secretion of microvesicles 
containing nanoparticles. The SPIOs enter in the cells via endocytosis trafficking and 
therefore they traffic to early endosomes (1). From there, the vesicles containing 
SPIOs mature in late endosomes or multivesicular bodies (MVB) (2) and then finally 
fuse to either lysosomes (3) or auotphagosomes (4) to create respectively lysosomes 
and autolysosomes. These matured vesicles could then be secreted outside the cell as 
whole structures (6).  
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This hypothesis is supported by previous knowledge of similar mechanisms in 
endothelial cells. These cells are naturally programmed to control the passage of fluids 
and molecules through vessel walls and one of the mechanisms they exploit is 
transcytosis. During this process they internalize cargos from the lumen side and 
subsequently release it in the interstitial space; an example is the GP60 receptor- 
mediated transcellular transport of albumin across the endothelium 71. Therefore 
vascular cells present the machinery to perform exocytosis. Vascular endothelial growth 
factor (VEGF)-activated endothelial cells 72 have also recently been shown to release 
specialized granules, called Weibed-Palade bodies (WPb), which are up to 3 µm in 
length and 0.1-0.2 µm in width 73, comparable with our vesicle size. 
  
Figure 21 A) Confocal images of FITC
SPIOs are visualized in reflectance. B) 
labeled secreted vesicles incubated 2
visualized in bright field and th
 
 
-Lamp1 labeled secreted vesicles, 
Confocal images of FITC-
4 hours with 4T1 cancer cells. 4
eir nuclei are stained with DAPI. 
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3.3.3 Intercellular Transfer of Nanoparticles through Microvesicles. 
In order to test if endothelial cell derived microvesicles could be involved in the 
inter-cellular transfer of nanoparticles, Lamp1-FITC labeled microvesicles were 
incubated with 4T1 breast cancer cells for 24 hours. Confocal microscopy of the treated 
cells (Figure 21, B-C) revealed an association of the FITC-vesicles with the cancer 
cells. The presence of SPIOs clusters within the green vesicles was detected by 
reflectance while the cell morphology was assessed by staining the nuclei with DAPI 
and visualizing the cell borders with bright field. To confirm microvesicle uptake by 
recipient cells we also performed TEM imaging on three different cell lines incubated 
overnight with the concentrated pellet secreted by endothelial cells (Figure 22). 
HMVECs (Figure 22-A) cells as well as two breast cancer cell lines, MCF7 and 4T1 
(respectively Figure 22 B and C), were employed for the experiment. From the TEM 
micrographs we can clearly see the presence of iron oxide nanoparticles confined in 
vesicles within the recipient cells.  
Together the confocal and TEM data suggest the uptake of the cell-released 
microvesicles containing SPIOs by recipient cells and therefore their possible role as a 
mediator of nanoparticles transport between different cells. The process is complex and 
dynamic as the vesicles can be re-internalized by other endothelial cells or by different 
types of cells, such as cancer cells. Similar results were obtained by Luciani et al. 54c, 
although their study was limited to macrophages as donor and recipient cells. Our data 
therefore extends the study to a wider range of cells suggesting a more ubiquitous 
presence of this process. Given their bio-genesis, the use of these microvesicles as 
carriers for nanoparticles would provide additional advantages in term of compatibility, 
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cellular uptake and trafficking, as compared to synthetic biovesicles, such as 
magnetoliposomes, which have already shown to enhance the contrast agent properties 
of SPIOs due to their confinement 74.  
From a broader point of view, since the vasculature represents a biological 
barrier in vivo for i.v. injected drug carriers, which has to be overcome in order to reach 
the lesion site 20b 29, 75, we therefore propose that the biological vesicles could be 
exploited to allow nanoparticles to cross the endothelial barrier and transfer particles 
and drugs to tumor cells. Although further studies are necessary to fully characterize the 
pathway, we can speculate that in the tumor environment, where VEGF concentration is 
high, secretion of biovesicles could be potentially more prevalent, as shown for WPb, 
leading to substantial release of microvesicles containing S2NPs.   
This finding expands our previous data reporting evidence of exocytosis of 
nanoparticles from HMVECs upon treatment with a MSVs loaded with amino-PEG 
SPIOs 64. The hypothesized mechanism of secretion could give insights into the long 
term fate of the unique vesicles that were budding overtime from the endosome 
encapsulating the silicon carrier. The novel vesicles were shown to independently traffic 
in the cells and they could potentially be secreted as a whole structure explaining the 
increase of iron in the supernatant.  
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Figure 22 TEM micrographs of recipient cells. A) HMVECs B) MCF7 C) 4T1 
incubated overnight with secreted microvesicles. In each line represent consecutive 
zooms highlighting the presence of iron oxide nanoparticles in the up taken vesicles. 
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4 Conclusions 
In summary, in this work we investigated the cellular trafficking of our 
multistage drug delivery system, assembled by loading porous silicon microparticles 
with super-paramagnetic iron oxide nanoparticles, in endothelial cells. 
 The first part of the study was focused on the understanding of the intracellular 
localization and migration properties of the silicon carriers. We demonstrate that the 
regardless the size (1.6 or 3.2 µm) or the surface functionalization (APTES vs oxidized) 
the silicon carriers are internalized by endothelial cells through phagocytosis and end up 
in the cells encapsulated in vesicles (phagosomes). These phagosomes are able to 
mature and move toward the perinuclear region through an active-microtubule-mediated 
mechanism. The rate of migration for different variations of microparticles was 
characterized and no impact on the microparticle size, charge and shape was observed. 
We also studied the long-termfate of the particles with respect to cell proliferation and 
intercellular transfer, highlighting particle partitioning between daughter cells as well as 
intercellular transfer.  
 The second part of the study was instead focused on the loading of the 
multistage system with second stage nanoparticles (SPIOs) and investigating the 
intracellular fate of the SPIOs once the MSVs were internalized in HMVECs. As 
expected, once internalized in the cells, MSVs were encapsulated in phagosomes, but 
the SPIOs were released over time from the pores and were sorted into unique vesicles 
(most likely multi-vesicular bodies) which were able to independently traffic inside the 
cells. Quantitative increase of iron over time in the supernatant suggested the possibility 
of iron oxide exocytosis. 
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This hypothesis was further investigated in the third and last part of the work 
where, through ultra-structural analysis of the conditional medium of HMVECs 
incubated with SPIOs, it was possible to identify endothelial-cell secreted biovesicles 
containing iron oxide nanoparticles. The morphology and dimension suggest that these 
microvesicles are lysosomal in origin with combined features of multivesicular bodies 
and autophagosomes. This result supports the possibility of a more ubiquitous presence 
of the release of microvesicles among cells which are not part of the phagocytic 
immunosystem and provides further insights into the long term fate of nanoparticles in 
cells. These microvesicles can also mediate the transfer of SPIOs between cells, not 
only between endothelial cells but also between cancer cells, we therefore propose that 
the biological event of intercellular transfer of nanoparticles within vesicles could be 
exploited to allow nanoparticles to cross the endothelial barrier and provide signals or 
therapeutics to tumor cells. 
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